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ABSTRACT 
Objectives: Heart rate slowing with ivabradine reduced cardiovascular death or heart 
failure hospitalizations among patients with chronic systolic heart failure (CHF) in the 
Systolic Heart Failure Treatment With the If Inhibitor Ivabradine Trial (SHIFT). 
Subsequently, heart rate slowing in the Study Assessing the Morbidity-Mortality Benefits 
of the If Inhibitor Ivabradine in Patients With Coronary Artery Disease (SIGNIFY) in 
patients without CHF provided no benefit for cardiovascular death or nonfatal 
myocardial infarction (primary composite endpoint); secondary analyses suggested 
possible harm in the angina subgroup. Therefore, we examined the impact of ivabradine 
among patients with CHF plus angina in SHIFT.  
Methods: SHIFT enrolled adults with stable, symptomatic CHF; left ventricular ejection 
fraction ≤35%; and sinus rhythm with resting heart rate ≥70 bpm. Outcomes were the 
SHIFT and SIGNIFY primary composite endpoints and their components. 
Results: Of 6505 patients in SHIFT, 2220 (34%) reported angina at randomization. 
Ivabradine numerically, but not significantly, reduced the SIGNIFY primary composite 
endpoint by 8%, 11%, and 11% in the SHIFT angina subgroup, nonangina subgroup, 
and overall population, respectively. Ivabradine also reduced the SHIFT primary 
composite endpoint in all three subgroups.   
Conclusions: Ivabradine did not increase cardiovascular death or nonfatal myocardial 
infarction in CHF patients with angina. 
Word Count: 199 
Keywords: angina, heart failure, heart rate, ivabradine  
  
INTRODUCTION 
Resting heart rate, as it increases, is directly associated with increased mortality and 
morbidity in patients with chronic systolic heart failure (CHF) in sinus rhythm [1,2]. 
Pharmacologically reducing heart rate improves outcomes in patients with systolic CHF, 
as is demonstrated in trials of beta blockers [3,4] and, most recently, of ivabradine, in 
the Systolic Heart Failure Treatment With the If Inhibitor Ivabradine Trial (SHIFT) [5].  
Relatively high resting heart rate also is directly associated with  mortality and 
myocardial infarction in patients with chronic stable coronary artery disease (CAD) [6,7]. 
However, in two large, randomized trials of ivabradine in patients with CAD, Morbidity-
Mortality Evaluation of the If Inhibitor Ivabradine in Patients With Coronary Disease and 
Left Ventricular Dysfunction (BEAUTIFUL) and Study Assessing the Morbidity-Mortality 
Benefits of the If Inhibitor Ivabradine in Patients With Coronary Artery Disease 
(SIGNIFY), ivabradine did not alter cardiac outcomes in patients with CAD with or 
without left-ventricular dysfunction [8,9]. However, a prespecified subgroup analysis of 
SIGNIFY suggested that patients with CAD and angina had worse outcomes with 
ivabradine than with placebo [8].  
These contrasting results raise concern that ivabradine may be associated with reduced 
efficacy or worsened cardiovascular outcomes in patients with CHF who have CAD, 
particularly those with angina [10]. To resolve this issue, we conducted a post hoc 
analysis to determine the outcomes of the patients in SHIFT who reported angina at 
enrollment and compared these results with those of the overall SHIFT population and 
with those who did not report angina. We also assessed the SIGNIFY outcomes in 
these SHIFT-based subgroups.  
  
METHODS 
Patients 
In SHIFT, enrolled adults had stable, symptomatic CHF, left ventricular ejection fraction 
(LVEF) ≤35% and were in sinus rhythm with resting heart rate ≥70 bpm. Full eligibility 
criteria have been described previously [5]. Evaluable patients from SHIFT were divided 
into subgroups based on the presence or absence of angina as reported by the 
investigator at study enrollment. The angina subgroup included all patients with a 
history of angina (reported as angina pectoris, microvascular angina, postinfarction 
angina, Prinzmetal angina, etc.) who answered “yes” to the question, “is the disease still 
present?” at enrollment. The SHIFT nonangina subgroup included all other patients in 
the overall SHIFT population.  
Clinical Outcomes 
The ivabradine and placebo groups from SHIFT were compared in the overall 
randomized set, the angina subgroup, and the nonangina subgroup. Outcomes were 
the primary composite endpoints of the SHIFT and SIGNIFY trials, as well as their 
individual components [5,8]. For SHIFT [5], these components included cardiovascular 
death or first hospitalization for worsening heart failure; for SIGNIFY [8], they included 
cardiovascular death or first nonfatal myocardial infarction. Adverse events were 
tabulated by randomized treatment group and angina and nonangina subgroups. 
Statistical Analysis 
The treatment effect was estimated using an adjusted Cox proportional hazards model 
with beta blocker intake at randomization as a covariate, as described in previous 
SHIFT publications; P-values for interaction between randomized treatment and 
  
subgroup status were also provided by addition of treatment by subgroup interaction to 
the model [5]. The safety analysis set included all patients who received at least one 
dose of ivabradine.   
  
RESULTS 
Patients 
Of the 6505 patients randomized in SHIFT, 2220 (34%) reported angina at enrollment 
and comprised the angina subgroup. The remaining 4285 patients (66%) formed the 
nonangina subgroup. Demographic and disease characteristics are summarized in 
Table 1. Briefly, patients with angina at baseline tended to be slightly older, numerically 
had higher blood pressure, more severe heart failure, and more beta blocker use than 
those without angina. Within each subgroup, there were no  significant differences 
between those who received ivabradine and those who received placebo. 
Clinical Outcomes 
Placebo-corrected average change in heart rate at 28 days for patients treated with 
ivabradine was –10.9 bpm (95% CI, −11.4 to −10.4) for the overall SHIFT population [5] 
and –10.8 bpm (95% CI, −11.7 to −10.0) and –11.0 bpm (95% CI, −11.6 to −10.3) for 
the angina and nonangina subgroups, respectively.  
Results for the SHIFT primary composite endpoint (cardiovascular death or hospital 
admission for worsening heart failure) were similar for those with and without angina 
and for the overall population (Figure 1). In the SHIFT angina subgroup  there were 
15% fewer events in the ivabradine arm compared with placebo but this did not reach 
statistical significance (hazard ratio [HR], 0.85; 95% CI, 0.73–1.00; P=0.055). There was 
a 20% reduction of events in the nonangina subgroup (HR, 0.80; 95% CI, 0.71–0.90; 
P<0.0001), and 18% reduction in the overall SHIFT population (HR, 0.82; 95% CI, 0.75–
0.90; P<0.0001). The effects of ivabradine on the components of the SHIFT primary 
  
composite endpoint were also similar among the overall SHIFT population, the SHIFT 
angina subgroup, and the SHIFT nonangina subgroup. 
The rates of on-treatment adverse events and adverse events of interest (defined in 
Table 2) in the angina and nonangina subgroups were consistent with those for the 
overall SHIFT population, with bradycardia and phosphenes/blurred vision being 
reported more frequently with ivabradine than placebo (Table 2) 
When the SIGNIFY endpoints were applied to the SHIFT population, results were 
similar among the three SHIFT-based groups for the primary composite endpoint of 
cardiovascular death and nonfatal myocardial infarction as well as for its components 
(Figure 2). A test of interaction between randomized treatment and presence/absence 
of angina showed no significant interaction (P=0.80). There were numerically fewer 
cases of cardiovascular death or nonfatal myocardial infarction in the ivabradine group 
compared with placebo in the SHIFT angina subgroup (HR, 0.92; 95% CI, 0.75–1.12; 
P=0.38); this tendency was similar in the SHIFT nonangina subgroup (HR, 0.89; 95% 
CI, 0.76–1.03; P=0.12), and in the overall SHIFT population (HR, 0.89; 95% CI, 0.79–
1.01; P=0.07), but none of these differences reached statistical significance. There were 
numerically fewer nonfatal myocardial infarctions in the ivabradine arm versus placebo 
(HR, 0.86; 95% CI, 0.53–1.40; P=0.55) in the SHIFT angina subgroup and the SHIFT 
overall population (HR, 0.93; 95% CI, 0.67–1.30; P=0.68), whereas there were similar 
numbers of non-fatal infarctions in both treatment arms in the nonangina subgroup (HR, 
1.02; 95% CI, 0.65–1.60; P=0.12) . 
  
DISCUSSION 
Resting heart rate is a known and modifiable risk factor in heart failure when patients 
are in sinus rhythm. Thus, as heart rate increases, adverse outcomes increase, and 
when heart rate is pharmacologically slowed, adverse outcomes diminish [11].  
However, in patients with cardiovascular disease without left ventricular dysfunction or 
CHF, increasing heart rate is a risk marker, indicating that other processes (eg, 
diabetes, smoking) are influencing the development of myocardial infarction or 
cardiovascular death [12]; modification of the marker does not appear to modify the 
disease [8,9]. Given the lack of efficacy of ivabradine in patients with angina and without 
CHF in the SIGNIFY trial, evaluation of the efficacy and safety of ivabradine in other 
patient groups with angina was needed. Because patients with systolic CHF often have 
underlying CAD and may also experience angina, it is possible that this subgroup of 
patients with CHF may have a different response to ivabradine compared to those with 
CHF without underlying angina. Therefore, this post hoc analysis evaluated the effects 
of heart rate slowing with ivabradine among the subgroup of SHIFT patients with CHF 
and angina. 
The worsening outcomes seen in the SIGNIFY population with angina (which had no 
CHF and no overlap in LVEF with the SHIFT population) were not observed in the 
SHIFT population. For the SHIFT and SIGNIFY primary composite endpoints and their 
components, results for the SHIFT angina subgroup were directionally consistent with 
both the SHIFT overall population and the SHIFT nonangina subgroup. Specifically, 
ivabradine numerically (but not significantly) reduced the SIGNIFY primary composite 
endpoint of cardiovascular death or nonfatal myocardial infarction versus placebo for 
  
both SHIFT subgroups and significantly in the overall SHIFT population. Similar results 
were observed for nonfatal myocardial infarction, with the exception of the nonangina 
group, in which a nonsignificant increase of 2% was observed for ivabradine versus 
placebo. However, patients without angina are known to have a lower risk of myocardial 
infarction compared with those with angina; therefore, any increase in myocardial 
infarction in these patients due to ivabradine is likely to be limited.  
The results of this analysis suggest that in patients with systolic CHF (and specifically in 
a population defined as in SHIFT), the risk of cardiovascular death or hospitalization for 
worsening heart failure is consistently reduced by heart rate slowing with ivabradine 
among patients with or without angina. Patients in the nonangina subgroup who 
received ivabradine achieved a statistically significant reduction in the risk of the SHIFT 
primary composite endpoint (cardiovascular death or hospitalization for worsening heart 
failure) compared with placebo. Patients in the angina subgroup tended to benefit from 
ivabradine, although the treatment difference was not statistically significant versus 
placebo (P=0.055). The lack of significance may relate to the limited power to detect 
differences in the relatively small angina subgroup, which was half the size of the 
nonangina cohort. These results are consistent with those observed from previous post 
hoc analyses of ivabradine use in patients with stable CAD and left ventricular systolic 
dysfunction. BEAUTIFUL evaluated ivabradine up to 7.5 mg twice daily in 10,917 
patients with CAD and LVEF <40% [9]. In that study, there was a significantly higher 
rate of cardiovascular death and hospital admissions for heart failure in patients with 
heart rate ≥70 bpm at baseline compared with those with heart rate <70 bpm at baseline 
[13]. Furthermore, ivabradine did not significantly affect the rate of the primary 
  
composite endpoint (cardiovascular death or hospitalization for myocardial infarction or 
new-onset/worsening heart failure) or of cardiovascular death alone. However, it did 
lead to a reduction in the secondary endpoints (hospitalization for myocardial infarction 
and coronary revascularization) among patients in BEAUTIFUL whose heart rate was 
≥70 bpm at randomization (a prespecified subanalysis) [9]. Conversely, in the 1507 
patients from BEAUTIFUL whose limiting symptom at baseline was angina, ivabradine 
was associated with a 24% reduction in the primary composite endpoint (HR, 0.76; 95% 
CI, 0.58–1.00; P=0.05) [14]. In addition, a 12% reduction in cardiovascular death (HR, 
0.88; 95% CI, 0.62–1.27; P=0.51) and a 16% reduction in hospitalization for worsening 
heart failure (HR, 0.84; 95% CI, 0.53–1.33; P=0.99) were seen, although these 
reductions did not reach statistical significance [14]. Our results and those observed in 
BEAUTIFUL suggest that the reduction in hospitalization for worsening heart failure 
observed in SHIFT is generalizable to the subset of patients with CHF and angina. 
It is not clear why the SHIFT results differ from those of SIGNIFY. Several possible 
explanations might be considered. First, of course, the phenotypes of the study 
populations differed markedly in SHIFT versus SIGNIFY. As noted previously, there was 
no overlap in the baseline LVEF between the two studies; CHF was present in all SHIFT 
patients but in no patients in SIGNIFY patients. Drug doses were allowed to be higher in 
SIGNIFY than in SHIFT, and the background therapies for CHF, required in SHIFT, 
were not required and often were absent in SIGNIFY, used only if indicated for some 
non-CHF comorbidity. Indeed, in an overarching review of the experience in SHIFT, 
BEAUTIFUL, and SIGNIFY, it was concluded that the efficacy of heart rate slowing with 
ivabradine in preventing angina does not translate into mitigation of pathologic 
  
alterations in the coronary arteries or to the sudden or gradual progression of these 
lesions that underlie clinical sequelae in CAD. However, heart rate slowing has a 
profound effect on myocardial biology, leading to the functional improvement and relief 
of CHF and its sequelae [12]. 
 Although the latter conclusion is empirically correct, the fundamental basis for the 
different effects of heart rate on arteries and myocardium is not clear and is the subject 
of speculation. The processes underlying these differences may include a differential 
depletion in myocardial norepinephrine levels in early-stage CHF that occurs before the 
onset of symptomatic heart failure [15], which may preferentially affect the myocardium 
compared with the coronary arteries. Another possible explanation is that heart rate 
slowing with ivabradine has a differential effect on arterial wave form reflections/arterial 
stiffness in patients with CHF [16] compared to those without, such as those with 
chronic CAD in SIGNIFY. Prior studies have suggested that beta blockers can increase 
pulse wave reflections/arterial stiffness, thereby negating the blood pressure–lowering 
effects on cardiovascular mortality and specifically precluding reduction of central aortic 
blood pressure, which may be attributable in part to heart rate reduction [17]. However, 
a crossover study specifically examining ivabradine versus beta blocker showed no 
effect of ivabradine on central aortic pressure [18]. Therefore, central pulse wave 
reflections and blood pressure effects are unlikely to explain the results of SIGNIFY or 
to negate the results of SHIFT in patients with CAD with or without angina. 
Several limitations must be considered in interpreting the results of this study. This was 
a post hoc analysis; therefore, it was designed to generate rather than to test a 
hypothesis. Also, angina was reported by SHIFT investigators with no protocol-specified 
  
definition. Consequently, the potential exists for bias in reporting or determination of the 
symptom. Finally, the power to discriminate among differences in group results was 
relatively limited, and several of the nominal differences did not reach statistical 
significance, limiting the strength of conclusions.  
Nonetheless, this post hoc analysis demonstrates that ivabradine treatment is 
acceptably safe in patients with moderate to severe CHF and, specifically, among those 
who also have angina pectoris. The analysis also suggests that outcome benefits of 
ivabradine among such patients are similar to those seen in individuals without angina 
and to all patients with CHF.    
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TABLES 
Table 1. Demographic and Disease Characteristics* 
 Angina Subgroup Nonangina Subgroup 
Characteristic 
Ivabradine 
(n=1085) 
Placebo 
(n=1135) 
Ivabradine 
(n=2156) 
Placebo 
(n=2129) 
Age, y  62.8±10.0 62.3±9.7 59.7±11.7 58.9±12.2 
Men, n (%) 807 (74.4) 887 (78.1) 1655 (76.8) 1621 (76.1) 
Current smoker, n (%) 208 (19.2) 211 (18.6) 333 (15.4) 366 (17.2) 
BMI, kg/m2 28.5±4.7 28.5±4.6 27.8±5.2 27.7±5.2 
Resting heart rate, bpm 79.0±8.9 79.7±9.8 80.0±9.8 80.3±9.7 
SBP, mmHg 124.7±14.9 124.1±15.1 120.6±16.5 119.9±16.0 
DBP, mmHg 77.1±8.9 76.8±8.9 75.1±9.9 75.0±9.6 
LVEF, % 30.1±4.6 30.0±4.5 28.5±5.3 28.4±5.4 
eGFR, mL/min/1.73 m2 73.5±21.1 73.0±20.5 75.1±23.8 75.8±24.2 
NYHA class II, n (%) 405 (37.3) 431 (38.0) 1180 (54.7) 1153 (54.2) 
NYHA class III/IV, n (%) 680 (62.7) 704 (62.0) 975 (45.2) 975 (45.8) 
Beta blocker at baseline, n (%) 1005 (92.6) 1042 (91.8) 1892 (87.8) 1881 (88.4) 
Beta blocker at target daily 
dose, n (%) 
334 (30.8) 297 (26.2) 409 (19.0) 448 (21.0) 
*Values are mean ± SD unless otherwise noted. 
BMI=body mass index; DBP=diastolic blood pressure; eGFR=estimated glomerular filtration 
rate; LVEF=left ventricular ejection fraction; NYHA=New York Heart Association; SBP=systolic 
blood pressure. 
  
Table 2. Adverse Events 
 Angina Subgroup Nonangina Subgroup SHIFT Safety Set 
Event, n (%) 
Ivabradine 
(n=1082) 
Placebo 
(n=1132) 
Ivabradine 
(n=2150) 
Placebo 
(n=2128) 
Ivabradine 
(n=3232) 
Placebo 
(n=3260) 
Overall adverse events       
Any adverse event 838 (77.4) 860 (76.0) 1576 (73.3) 1532 (72.0) 2439 (75.5) 2423 (74.3) 
Serious adverse events 485 (44.8) 529 (46.7) 884 (41.1) 952 (44.7) 1450 (44.9) 1553 (47.6) 
Adverse event leading to treatment 
discontinuation 
155 (14.3) 129 (11.4) 312 (14.5) 287 (13.5) 467 (14.5) 416 (12.8) 
Adverse events of interest       
AV block II–III 10 (0.9) 3 (0.3) 23 (1.1) 15 (0.7) 33 (1.0) 18 (0.6) 
Atrial fibrillation 88 (8.1) 81 (7.2) 179 (8.3) 136 (6.4) 267 (8.3) 217 (6.7) 
Bradycardia* 142 (13.1) 39 (3.5) 180 (8.4) 33 (1.6) 322 (10.0) 72 (2.2) 
Phosphenes-blurred vision 30 (2.8) 9 (0.8) 76 (3.5) 13 (0.6) 106 (3.3) 22 (0.7) 
AV=atrioventricular. 
*Includes symptomatic and asymptomatic bradycardia 
 
 
  
FIGURE LEGENDS 
Figure 1. Effect of ivabradine versus placebo on clinical outcomes (SHIFT endpoints) 
among patients with moderate to severe chronic systolic heart failure with left ventricular 
dysfunction (SHIFT trial population) with and without angina.  CV=cardiovascular; 
CHF=chronic heart failure; SHIFT=Systolic Heart Failure Treatment With the If Inhibitor 
Ivabradine Trial. 
Figure 2. Effect of ivabradine versus placebo on clinical outcomes (SIGNIFY endpoints) 
among patients with moderate to severe chronic systolic heart failure with left ventricular 
dysfunction (SHIFT trial population) with and without angina.  CV=cardiovascular; 
MI=myocardial infarction; SHIFT=Systolic Heart Failure Treatment With the If Inhibitor 
Ivabradine Trial; SIGNIFY=Study Assessing the Morbidity-Mortality Benefits of the If 
Inhibitor Ivabradine in Patients With Coronary Artery Disease. 
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